Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics

Schizophrenia Research

Volumn 44, Issue 3, 2000, Pages 165-175

  Kim, Yong Ku ^a   Kim, Leen ^a   Lee, Min Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Interleukin; Neurotransmitter; Psychopathology; Schizophrenia

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CYTOKINE; HALOPERIDOL; HOMOVANILLIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; NEUROTRANSMITTER;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINERGIC SYSTEM; HUMAN; MALE; MENTAL DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALOPERIDOL; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; INTERLEUKINS; MALE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034283785     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00171-1     Document Type: Article

References (62)

1. Ader R., Cohen N., Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet. 345:1995;99-103.
2. Alonso R., Chaudieu I., Diorio J., Krishnamurthy A., Quirion R., Boksa B. Interleukin-2 modulates evoked release of [3H] dopamine in rat cultured mesencephalic cells. J. Neurochem. 61:1993;1284-1290.
3. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. 1994;American Psychiatric Press, Washington, DC.
4. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS). 1983;University of Iowa, Iowa City.
5. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS). 1983;University of Iowa, Iowa City.
6. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentrations in patients with schizophrenia. Schizophr. Res. 20:1996;199-203.
7. Bertini R., Garattini S., Delgado R., Ghezzi P. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice. Immunol. 79:1993;217-219.
8. Boukhris W., Kouassi E., Revillard J.P. Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro. Immunopharmacol. Immunotoxicol. 10:1988;501-512.
9. Caruso C., Candore G., Cigna D., Colucci A.T., Modica M.A. Biological significance of soluble IL-2 receptor. Med. Inflamm. 2:1993;3-21.
10. Crow T.J. Molecular pathology of schizophrenia: more than one disease process. Br. Med. J. 280:1980;66-68.
11. Davis K.L., Kann R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 148:1991;1474-1486.
12. De Jongh R., Vranken J., Vundelinckx G., Bosmans E., Maes M., Heylen R. The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. Cytokine. 9:1997;696-701.
13. DeLisi L.E., Goodman S., Neckers L.M., Wyatt R.J. An analysis of lymphocyte subpopulations in schizophrenic patients. Biol. Psychiatry. 17:1982;1003-1009.
14. Denicoff K.D., Rubinow D.R., Papa M.Z., Simpson C., Seipp C.A., Lotze M.T., Chang A.E., Rosenstein D., Rosenberg S.A. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med. 107:1987;293-300.
15. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiat. Clin. Neurosci. 247:1997;228-233.
16. Ganguli R., Rabin B.S. Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects. Arch. Gen. Psychiatry. 46:1989;292.
17. Ganguli R., Rabin B.S., Kelly R.H., Lyne M., Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. N.Y. Acad. Sci. 496:1987;676-685.
18. Ganguli R., Yang Z., Shurin G., Chengappa K.N.R., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51:1994;1-10.
19. Ganguli R., Brar J.S., Chengappa K.N.R., Deleo M., Yang Z.W., Shurin G., Rabin B.S. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. Arch. Gen. Psychiatry. 52:1995;668-672.
20. Gattaz W.F., Dalgalarrondo P., Schroder H.C. Abnormalities in serum concentrations of interleukin-2, interferon-α and interferon-γ in schizophrenia not detected. Schizophr. Res. 6:1992;237-241.
21. Gaughran F., O'Neill E., Cole M., Collins K., Daly R.J., Shanahan F. Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophr. Res. 29:1998;263-267.
22. Hanisch U.K., Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res. Rev. 21:1996;246-284.
23. Henneberg A., Riedl B., Dumke H.O., Kornhuber H.H. T lymphocyte subpopulations in schizophrenic patients. Eur. Arch. Psychiat. Neurol. Sci. 239:1990;283-284.
24. Katila H., Appelberg B., Hurme M., Rimon R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res. 12:1994;29-34.
25. Kim Y.K., Lee M.S., Hahm W., Lee K.H., Lee C.K. Relationships between acute phase proteins and activities of interleukin-1β, interleukin-6 in schizophrenic patients. Seoul J. Psychiatry. 19:1994;179-186.
26. Kim Y.K., Lee M.S., Suh K.Y. Decreased IL-2 production in Korean schizophrenic patients. Biol. Psychiatry. 43:1998;701-704.
27. Kirch D.G. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr. Bull. 19:1993;355-370.
28. Lapchak P.A. A role for IL-2 in the regulation of striatal dopaminergic function. Neuroreport. 3:1992;165-168.
29. Lapchak P.A., Araujo D.M., Quirion R., Beaudet A. Immunoautoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. Neurosci. 44:1991;173-184.
30. Leykin I., Mayer R., Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacol. 37:1997;75-86.
31. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am. J. Psychiatry. 150:1993;1408-1410.
32. Lieberman J.A., Koreen A.R. Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr. Bull. 19:1993;371-429.
33. Lin A., Kenis G., Bignotti S., Tura G.J.B., De Jongh R., Bosmans E., Pioli R., Altamura C., Scharpe S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32:1998;9-15.
34. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 89:1994;346-351.
35. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29:1995;141-152.
36. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., Berghmans R., Stans G., Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 21:1996;39-50.
37. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., Scharpe S. Acute phase proteins in schizophrenia, mania, and major depression: modulation by psychotropic drugs. Psychiatry Res. 66:1997;1-11.
38. Maes M., Bosmans E., Kenis G., De Jongh R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr. Res. 26:1997;221-225.
39. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., Yao J., Peters J.L. Increases in CSF levels of IL-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am. J. Psychiatry. 152:1995;1291-1297.
40. Muller N., Hofschuster E., Ackenheil M., Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiat. Scand. 87:1993;66-71.
41. Muller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiat. Clin. Neurosci. 247:1997;308-313.
42. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:1996;269-273.
43. Naudin J., Capo C., Giusano B., Mege J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia? Schizophr. Res. 26:1997;227-233.
44. Petitto J.M., McCarthy D.B., Rinker C.M., Huang Z., Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J. Neuroimmunol. 73:1997;183-190.
45. Plata-Salaman C.R. Immunoregulators in the nervous system. Neurosci. Biobehav. Rev. 15:1991;185-215.
46. Pollmacher T., Hinze-Selch D., Fenzel T., Kraus T., Schuld A., Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am. J. Psychiatry. 154:1997;1763-1765.
47. Rapaport M.H., McAllister C.G., Nelson D.L., Pickar D., Paul S.M. Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch. Gen. Psychiatry. 46:1989;291-292.
48. Rapaport M.H., McAllister C.G., Kim Y.S., Han J.H., Pickar D., Nelson D.L., Kirch D.G., Paul S.M. Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol. Psychiatry. 35:1994;767-771.
49. Riches P., Gooding R., Millar B.C., Rowbottom A.W. Influence of collection and separation of blood samples on plasma Il-1, Il-6 and TNF-α concentrations. J. Immunol. Meth. 153:1992;125-131.
50. Roth R.H., Bacopoulos N.G. Plasma dopamine metabolites: useful indices of central dopamine metabolism? Usdin E., Kopin I.J., Barchas J. Catechoamines: Basic and Clinical Frontiers. 1979;681-683 Pergamon Press, New York.
51. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiol. 37:1998;186-193.
52. Schmidt C.J., Sorensen S.M., Kehne J.H., Carr A.A., Palfreyman M.G. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 56:1995;2209-2222.
53. Seegal R.F., Brosch K.O., Bush B. High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and serum. J. Chromatogr. 377:1986;131-144.
54. Shintani F., Kanba S., Maruo N., Nakaki T., Nibuya M., Suzuki E., Kinoshita N., Yagi G. Serum interleukin-6 in schizophrenic patients. Life Sci. 49:1991;661-664.
55. Sirota P., Schild K., Elizur A., Djaldetti M., Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiat. 19:1995;75-83.
56. Smith R.S., Maes M. The macrophage-T lymphocyte theory of schizophrenia: additional evidence. Med. Hypoth. 45:1995;135-141.
57. Spitzer R.L., Williams J.B., Gibbon M., First M.B. Instruction Manual for the Structured Clinical Interview for DSM-IV (SCID). 1995;Biometrics Research Division, New York State Psychiatric Institute, New York.
58. Thavasu P.W., Longhurst S., Joel S.P., Slevin M.L., Balkwill F.R. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J. Immunol. Meth. 153:1992;115-124.
59. Villemain F., Chatenoud L., Galinowski A., Homo-Delarche F., Ginestet D., Loo H., Zarifian E., Bach J.F. Aberrant T cell-immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry. 146:1989;609-616.
60. Waddington J.L. Neurodynamics of abnormalities in cerebral metabolism and structure in schizophrenia. Schizophr. Bull. 19:1993;55-69.
61. Whicher J., Ingham E. Cytokine measurements in body fluids. Eur. Cytokine Netw. 1:1990;239-243.
62. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D.G., Anisman H., Greenberg A.H. Cytokine-specific central monoamine alterations induced by IL-1, -2 and -6. Brain Res. 643:1994;40-49.